Regeneron Pharmaceuticals

This study tested an experimental drug called REGN7257 in 17 people with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. The drug was given to patients whose disease did not get better or came back after standard immune-suppressing …

This study tested a new combination treatment for people with advanced melanoma that cannot be removed by surgery or has spread. The combination included an experimental drug injected into tumors (CMP-001) plus an immunotherapy given through a vein (nivolumab). It was compared to…

This study tested whether injecting vidutolimod directly into tumors plus giving cemiplimab through a vein could shrink cancers that have spread. The trial included 77 people with several types of advanced cancer. Unfortunately, the study was stopped early, so we have less inform…

This early-stage study tested a new treatment called BPX-601 for people with advanced prostate cancer that had stopped responding to other therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells carrying a specific marker (PSCA). …

This study tested a single dose of an experimental antibody called REGN5381 in 89 people with chronic heart failure and reduced pumping ability. The goal was to check safety, how the drug moves in the body, and its effects on heart stress markers. The trial was terminated early, …

This study tested an experimental drug called REGN5093-M114, alone or with another drug, in people with advanced non-small cell lung cancer that has too much MET protein. The goal was to find a safe dose and see if it could shrink tumors. The study was stopped early, but the resu…

This early-stage study tested a new antibody drug (REGN14256) alone or with imdevimab in 25 adults with mild COVID-19 and no risk factors for severe illness. The goal was to check safety and whether the drug could lower virus levels. However, the trial was terminated early, so we…

This study tested an experimental drug called REGN5381 in 34 adults with uncontrolled hypertension (high blood pressure despite taking one or more blood pressure medications). The drug is a monoclonal antibody designed to activate NPR1 receptors, which may help lower blood pressu…

This early-phase study tested a new treatment called bbT369 for people with a type of blood cancer (B cell non-Hodgkin's lymphoma) that had come back or stopped responding to other treatments. The therapy uses a patient's own immune cells, which are modified to better recognize a…

This study tested a single injection of two lab-made antibodies (casirivimab and imdevimab) in children under 12 who are at high risk for severe COVID-19. The goal was to see how the drug behaves in the body, if it is safe, and if it triggers an immune response. Only 7 children t…

This phase 2 trial tested a drug called REGN4461 (mibavademab) in 20 people with familial partial lipodystrophy, a rare condition causing abnormal fat distribution and metabolic problems. The study aimed to see if the drug could lower high triglycerides and improve blood sugar co…

This study tested a single dose of casirivimab+imdevimab (REGN-COV2) in children hospitalized with COVID-19. The goal was to see how the drug behaves in the body and whether it is safe. However, the study was terminated early and only enrolled 2 participants, so we have very litt…

This study tested whether a combination of antibodies (casirivimab+imdevimab) could prevent COVID-19 in people with weakened immune systems, such as transplant recipients or cancer patients. Participants received either the antibodies or a placebo as a shot under the skin. The tr…